ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
24 announcements with these filters
Vivo Bio Tech has sent letters to shareholders without registered email addresses, providing a web-link to access the Annual Report for the financial year 2025-26.
Vivo Bio Tech Limited has submitted its Annual Report for the financial year 2025-2026 along with the notice for its 39th Annual General Meeting.
Vivo Bio Tech Ltd issued a notice for its 39th Annual General Meeting to be held on September 30, 2026, via video conferencing.
P.K.L Solution Private Limited, a promoter group entity, sold 6,00,000 equity shares of Vivo Bio Tech Limited. This off-market transaction reduced their stake to nil.
Vivo Bio Tech Limited announced the re-appointment of Mr. Sri Kalyan Kompella and Mr. Sankaranarayanan Alangudi as Executive Directors of the company.
Vivo Bio Tech's board meeting approved the 39th AGM date and the re-appointment of three Whole-Time Directors.
Vivo Bio Tech Limited announced that 8,10,000 promoter-allotted warrants have expired due to non-exercise within the 18-month tenure.
Vivo Bio Tech Limited announced that 483 outstanding convertible equity warrants have expired due to non-exercise within the eighteen-month tenure.
Vivo Bio Tech Ltd filed its routine quarterly shareholding pattern for the period ending June 30, 2026.
Vivo Bio Tech shareholders approved the re-appointment of Kalyan Ram Mangipudi as Whole-time Director. Related party transactions with a promoter and Virinchi Limited were also approved.
Vivo Bio Tech Ltd reported revenue from operations of ₹14.3 Cr (+14.4% YoY) and net profit of ₹0.2 Cr (-84.6% YoY) for Q1 FY27.
Vivo Bio Tech Ltd will hold a Board Meeting on July 13, 2026, to approve Q1 FY27 financial results. Trading window is closed for insiders until July 15, 2026.
Vivo Bio Tech announced the resignation of Mr. A V Kiran as Company Secretary. Mr. Bhavish Vijayvargiya was appointed to the role effective June 24, 2026.
Shri Shri Resorts Private Limited, a promoter group entity, sold 67,000 shares of Vivo Bio Tech Limited. This open market transaction reduces their stake by 0.30%.
Vivo Bio Tech Ltd announced a postal ballot notice for electronic voting on three resolutions, including a director re‑appointment and related‑party approvals. Voting runs from June 15 to July 14 2026.
Shri Shri Resorts Private Limited, a promoter group entity, sold 10,00,000 equity shares of Vivo Bio Tech Limited on the open market. This reduces their stake.
Vivo Bio Tech Ltd reported revenue from operations of ₹14.2 Cr (+15.4% YoY) and a net loss of ₹5.2 Cr for Q4 FY26.
Vivo Bio Tech approved its FY26 audited financial results and the re-appointment of Mr. Kalyan Ram Mangipudi as Whole-time Director. The company also appointed a consultant for an upcoming merger scheme.
Vivo Bio Tech Ltd postponed its Board Meeting from May 29 to May 30, 2026. The meeting will discuss quarterly financial results and a proposed amalgamation.
Vivo Bio Tech scheduled a May 29 board meeting to approve annual financial results and an amalgamation. Investors should monitor for subsequent merger and performance updates.
Vivo Bio Tech Limited submitted its Annual Secretarial Compliance Report for the financial year 2026. This filing fulfills regulatory disclosure requirements under SEBI (LODR) Regulations.
Vivo Bio Tech Limited reported zero requests for the re-lodgement of physical share transfers for the period ended March 2026. This routine SEBI compliance filing, received from the company's Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, confirms no activity in this category during the month.
Vivo Bio Tech Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI Regulations for the period ended March 31, 2026. The certificate confirms that security certificates received for dematerialisation were processed and cancelled by their Registrar, Aarthi Consultants Private Limited.
Vivo Bio Tech Ltd reported net profit of ₹1.2 Cr (+50.0% YoY) for Q3 FY26.